Immunostimulants drugs - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 1.40 [0.79, 2.49]> 10%1 study (1 / -)87.5 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.85 [0.91, 3.77]> 10%1 study (1 / -)95.5 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.20 [0.80, 1.80]> 10%1 study (1 / -)80.9 %some concernnot evaluable moderatecrucial-
clinical improvement (7-day) 0.98 [0.30, 3.20]> 10%1 study (1 / -)48.7 %some concernnot evaluable moderatecrucial-
deaths 0.65 [0.29, 1.46]< 10%1 study (1 / -)85.2 %some concernnot evaluable moderatecrucial-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 91